Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

FDA issues statement on Eucrisa for eczema In a controlled trial, participants receiving Eucrisa achieved clear or almost clear skin after 28 days of treatment. The FDA has approved ...

Pfizer acquired the Eucrisa (crisaborole) when it bought its developer, Anacor in May this year for $5.2 billion. Skip to main content Monday 17 June 2024 ...

Pfizer Inc. (NYSE:PFE) announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of ...

In December, Eucrisa became the first PDE-4 blocker approved to treat mild-to-moderate eczema for people ages 2 and older. Pfizer declined to comment on the campaign.

Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa for ...

Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.

Quick FDA approval of the eczema ointment Eucrisa has made Pfizer’s (NYSE:PFE) takeover of its originator Anacor Pharmaceuticals (ANAC) look like a reasonably canny move, but at $5.2bn the deal ...

Nearly 18 million children and adults across the United States live with atopic dermatitis (AD), also known as eczema.1 About 90 percent of those with eczema have the mild-to-moderate form of the d… ...

Pfizer has suggested that patient desire for an effective alternative to steroid drugs in eczema – also known as atopic dermatitis – could drive Eucrisa to sales of around $2bn-a-year. It needs the ...